Drug intelligence / Profile preview

SLX-200

Development stage: Unknown
Lead developer: Solaxa
Modality: Small Molecules

Overview

SLX-200 is a small molecule therapeutic being developed by Solaxa for the treatment of traumatic nerve injury. It is a repurposed aminopyridine that acts as an ion-channel modulator. The drug is designed to restore nerve function following injury by targeting specific ion channels, a mechanism typically associated with enhancing action potential conduction in damaged or demyelinated nerves. SLX-200 is currently in Phase 1 clinical development, aiming to address functional deficits in patients suffering from acute or chronic nerve damage.

Beyond the preview

Go deeper on SLX-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLX-200.

Explore the full profile